Sule Olajumoke, Brown Nicholas M, Willocks Lorna J, Day Jane, Shankar Sonal, Palmer Christopher R, Burrows Nigel P
Clinical Microbiology and Public Health Laboratory, Health Protection Agency, Box 236, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QW, UK.
Int J Antimicrob Agents. 2007 Jul;30(1):78-82. doi: 10.1016/j.ijantimicag.2007.02.015. Epub 2007 May 1.
We questioned 62 dermatology outpatients with atopic eczema and Staphylococcus aureus colonisation regarding their use of topical preparations containing fusidic acid during the previous 6 months as well as the pattern of any such use. Recent exposure to topical fusidic acid was significantly correlated with the presence of fusidic acid-resistant S. aureus (FRSA) (P=0.04). There was also a significant trend towards increasing FRSA carriage with increased duration of use. Short courses of 2 weeks or less did not appear to change the FRSA profile compared with non-exposure, and intermittent usage appeared to be the most detrimental, although subgroup sizes were small. Our study cautions against prolonged or intermittent use of fusidic acid-containing products in patients with eczema.
我们询问了62名患有特应性皮炎且金黄色葡萄球菌定植的皮肤科门诊患者，了解他们在过去6个月中使用含夫西地酸外用制剂的情况以及使用模式。近期接触外用夫西地酸与耐夫西地酸金黄色葡萄球菌（FRSA）的存在显著相关（P = 0.04）。随着使用时间的延长，FRSA携带率也有显著上升趋势。与未接触相比，2周或更短时间的短期疗程似乎并未改变FRSA情况，尽管亚组规模较小，但间歇性使用似乎最为有害。我们的研究告诫湿疹患者不要长期或间歇性使用含夫西地酸的产品。
